SFM
TVTX icon

Sphera Funds Management’s Travere Therapeutics TVTX Stock Holding History

Sphera Funds Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-101,800
Closed -$2.43M – 136
2025
Q3 		$2.43M Buy
+101,800
New +$1.91M 0.51% 64
2024
Q4 		– Sell
-170,700
Closed -$2.39M – 132
2024
Q3 		$2.39M Buy
+170,700
New +$1.78M 0.38% 75

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sphera Funds Management's TVTX Position: Q3 2025 in Review

Sphera Funds Management sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 335,333 shares — an estimated $6.3M sold.

Sphera Funds Management first reported a position in TVTX in Q1 2015 and held it in 23 quarters. The position peaked at $10.7M in Q2 2019. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Sphera Funds Management reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sphera Funds Management sold 335,333 Travere Therapeutics shares in Q3 2025, an estimated $6.3M.
  • Sphera Funds Management first reported a position in Travere Therapeutics in Q1 2015 and held it in 23 quarters.
  • Sphera Funds Management's Travere Therapeutics position peaked at $10.7M in Q2 2019.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.